IL323105A - RNAi agents for inhibiting expression of ataxin-2 (atxn2), their compositions and methods of use - Google Patents

RNAi agents for inhibiting expression of ataxin-2 (atxn2), their compositions and methods of use

Info

Publication number
IL323105A
IL323105A IL323105A IL32310525A IL323105A IL 323105 A IL323105 A IL 323105A IL 323105 A IL323105 A IL 323105A IL 32310525 A IL32310525 A IL 32310525A IL 323105 A IL323105 A IL 323105A
Authority
IL
Israel
Prior art keywords
rnai agent
invab
atxn2
nucleotides
nucleotide
Prior art date
Application number
IL323105A
Other languages
English (en)
Hebrew (he)
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of IL323105A publication Critical patent/IL323105A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL323105A 2023-03-17 2025-09-02 RNAi agents for inhibiting expression of ataxin-2 (atxn2), their compositions and methods of use IL323105A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363490866P 2023-03-17 2023-03-17
PCT/US2024/020125 WO2024196753A2 (en) 2023-03-17 2024-03-15 Rnai agents for inhibiting expression of ataxin-2 (atxn2), compositions thereof, and methods of use

Publications (1)

Publication Number Publication Date
IL323105A true IL323105A (en) 2025-11-01

Family

ID=92842271

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323105A IL323105A (en) 2023-03-17 2025-09-02 RNAi agents for inhibiting expression of ataxin-2 (atxn2), their compositions and methods of use

Country Status (11)

Country Link
EP (1) EP4680745A2 (de)
JP (1) JP2026509898A (de)
KR (1) KR20250164214A (de)
CN (1) CN121127589A (de)
AU (1) AU2024240456A1 (de)
CL (1) CL2025002777A1 (de)
CO (1) CO2025012510A2 (de)
IL (1) IL323105A (de)
MX (1) MX2025010867A (de)
TW (1) TW202444390A (de)
WO (1) WO2024196753A2 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4100527A2 (de) * 2020-02-07 2022-12-14 Maze Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung neurodegenerativer erkrankungen
US20240294906A1 (en) * 2020-07-29 2024-09-05 Alnylam Pharmaceuticals, Inc. Atxn2 irna compositions and methods of use thereof for treating or preventing atxn2-associated neurodegenerative diseases

Also Published As

Publication number Publication date
CN121127589A (zh) 2025-12-12
CO2025012510A2 (es) 2025-11-28
TW202444390A (zh) 2024-11-16
MX2025010867A (es) 2025-12-01
JP2026509898A (ja) 2026-03-25
WO2024196753A3 (en) 2024-11-07
KR20250164214A (ko) 2025-11-24
EP4680745A2 (de) 2026-01-21
AU2024240456A1 (en) 2025-10-23
CL2025002777A1 (es) 2025-12-19
WO2024196753A2 (en) 2024-09-26

Similar Documents

Publication Publication Date Title
JP7741927B2 (ja) １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法
AU2021242321B2 (en) RNAi agents for inhibiting expression of PNPLA3, pharmaceutical compositions thereof, and methods of use
WO2019055633A1 (en) RNAI AGENTS AND COMPOSITIONS FOR INHIBITING ANALOGUE EXPRESSION OF ANGIOPOIETIN 3 (ANGPTL3) AND METHODS OF USE
US20230357776A1 (en) Compositions and methods for modulating complement factor b expression
TW202334416A (zh) 用於抑制基質金屬蛋白酶7 (MMP7)之表現的RNAi藥劑、其組成物及使用方法
WO2023245060A2 (en) Rnai agents for inhibiting expression of superoxide dismutase 1 (sod1), compositions thereof, and methods of use
TW202440926A (zh) 用於抑制前蛋白轉化酶枯草桿菌蛋白酶KEXIN 9 (PCSK9)表現之RNAi 試劑及其醫藥組合物與使用方法
WO2025212467A1 (en) Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
EP4680249A1 (de) Rnai-mittel zur hemmung der expression der mitochondrialen amidoximreduzierenden komponente 1 (marc1), pharmazeutische zusammensetzungen davon und verfahren zur verwendung
EP4680745A2 (de) Rnai-mittel zur hemmung der expression von ataxin-2 (atxn2), zusammensetzungen davon und verfahren zur verwendung
WO2026060370A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF SYNUCLEIN ALPHA (SNCA), COMPOSITIONS THEREOF, AND METHODS OF USE
WO2025160224A1 (en) Rnai agents for inhibiting expression of androgen receptor (ar), compositions thereof, and methods of use
HK40084771B (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF PNPLA3, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
JP2026511018A (ja) 補体因子Ｂ（ＣＦＢ）の発現を阻害するためのＲＮＡｉ剤、その医薬組成物、及び使用方法
WO2026097000A1 (en) Rnai agents for inhibiting expression of interleukin 33 (il33), compositions thereof, and methods of use
HK40084771A (en) Rnai agents for inhibiting expression of pnpla3, pharmaceutical compositions thereof, and methods of use
EA047975B1 (ru) РНКи АГЕНТЫ ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ 17β-HSD ТИПА 13 (HSD17B13), ИХ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ